TCR-modified T cell therapy targeting HLA-restricted KRAS antigen (master protocol)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for TCR-modified T cell therapy targeting HLA-restricted KRAS antigen (master protocol), covering 2025-08-28 to 2025-08-28. Get the full timeline:
Most recent: Clinical Trial Update: Master Protocol of TCR-modified T Cell Therapy Targeting HLA-restricted KRAS Antigen Administered in Adult Patients With Metastatic or Locally Advanced PDAC [Phase 1, Phase 2]